Cargando…
Prolonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report
Renal cell carcinoma is one of the leading causes of cancer worldwide. Brain metastasis is a poor prognostic factor among patients with this disease. The advancements in understanding of the molecular framework behind malignancy and brain metastasis led to more sophisticated treatment regimens which...
Autores principales: | Mojica, Christianne V., Aguas, Gerard Vincent A., Cornelio, Gerardo Thomas H., Damian, Ludwig F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613622/ https://www.ncbi.nlm.nih.gov/pubmed/34899245 http://dx.doi.org/10.1159/000519745 |
Ejemplares similares
-
Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
por: Lu, Xiaolin, et al.
Publicado: (2021) -
Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and
Proarrhythmic Effects
por: Akman, Tulay, et al.
Publicado: (2014) -
Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
por: Roberto, Michela, et al.
Publicado: (2015) -
Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
por: Nikic, Predrag, et al.
Publicado: (2022) -
Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
por: Villa, Guillermo, et al.
Publicado: (2013)